{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:19:16Z","timestamp":1788981556514,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019305","name":"Manipal Academy of Higher Education","doi-asserted-by":"publisher","award":["IMF"],"award-info":[{"award-number":["IMF"]}],"id":[{"id":"10.13039\/100019305","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13318-026-01015-z","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:08:25Z","timestamp":1782454105000},"page":"601-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the Impact of Calcium Channel Blockers on the Pharmacokinetics of Lapatinib: Possible Role of Cytochrome P450 Enzymes and P-glycoprotein Efflux Transporters"],"prefix":"10.1007","volume":"51","author":[{"given":"Mrunal Pradeep","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajakta Harish","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anithakumari Uttam Singh","family":"Rajpurohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vullendula Sai Krishna","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-7499","authenticated-orcid":false,"given":"Jagadish Puralae","family":"Channabasavaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010.","journal-title":"Breast"},{"issue":"5","key":"1015_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.21037\/atm.2020.03.21","volume":"8","author":"X Ye","year":"2020","unstructured":"Ye X, Luo X, Du Q, Li H, Liu HY, Yu B, et al. Efficacy and safety of lapatinib in Chinese breast cancer patients: a real-world study. Ann Transl Med. 2020;8(5):240\u2013240. https:\/\/doi.org\/10.21037\/atm.2020.03.21.","journal-title":"Ann Transl Med"},{"key":"1015_CR3","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","volume":"15","author":"RWF Van Leeuwen","year":"2014","unstructured":"Van Leeuwen RWF, van Gelder T, Mathijssen RHJ, Jansman FGA. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15:e315\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(13)70579-5.","journal-title":"Lancet Oncol"},{"key":"1015_CR4","doi-asserted-by":"publisher","first-page":"E811","DOI":"10.1161\/CIR.0000000000001056","volume":"145","author":"CJ Beavers","year":"2022","unstructured":"Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, et al. Cardio-oncology drug interactions: a scientific statement from the american heart association. Circulation. 2022;145:E811\u201338. https:\/\/doi.org\/10.1161\/CIR.0000000000001056.","journal-title":"Circulation"},{"key":"1015_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","volume":"122","author":"D Eiger","year":"2020","unstructured":"Eiger D, Pond\u00e9 NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, et al. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab treatment optimization trial. Br J Cancer. 2020;122:1453\u201360. https:\/\/doi.org\/10.1038\/s41416-020-0786-x.","journal-title":"Br J Cancer"},{"key":"1015_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102822","volume":"145","author":"M Akbulut","year":"2020","unstructured":"Akbulut M, Urun Y. Onco-cardiology: drug-drug interactions of antineoplastic and cardiovascular drugs. Crit Rev Oncol Hematol. 2020;145:102822. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102822.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1015_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s10637-019-00806-3","volume":"38","author":"A Karbownik","year":"2020","unstructured":"Karbownik A, Soba\u0144ska K, P\u0142otek W, Grabowski T, Klupczynska A, Plewa S, et al. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. Investig New Drugs. 2020;38:574\u201383. https:\/\/doi.org\/10.1007\/s10637-019-00806-3.","journal-title":"Investig New Drugs"},{"key":"1015_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/03602532.2014.1003648","volume":"47","author":"HK Ho","year":"2015","unstructured":"Ho HK, Chan JCY, Hardy KD, Chan ECY. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. Drug Metab Rev. 2015;47:21\u20138. https:\/\/doi.org\/10.3109\/03602532.2014.1003648.","journal-title":"Drug Metab Rev"},{"key":"1015_CR9","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.toxrep.2022.10.004","volume":"9","author":"C Rodseeda","year":"2022","unstructured":"Rodseeda C, Yamanont P, Pinthong D, Korprasertthaworn P. Inhibitory effects of Thai herbal extracts on the cytochrome P450 3A-mediated metabolism of gefitinib, lapatinib, and sorafenib. Toxicol Rep. 2022;9:1846\u201352. https:\/\/doi.org\/10.1016\/j.toxrep.2022.10.004.","journal-title":"Toxicol Rep"},{"key":"1015_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10549-012-1995-7","volume":"133","author":"YL Teo","year":"2012","unstructured":"Teo YL, Saetaew M, Chanthawong S, Yap YS, Yong Chan EC, Ho HK, et al. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat. 2012;133:703\u201311. https:\/\/doi.org\/10.1007\/s10549-012-1995-7.","journal-title":"Breast Cancer Res Treat"},{"key":"1015_CR11","doi-asserted-by":"publisher","first-page":"19325","DOI":"10.1039\/C9RA03251G","volume":"9","author":"MM Alanazi","year":"2019","unstructured":"Alanazi MM, Alkahtani HM, Almehizia AA, Attwa MW, Bakheit AH, Darwish HW. Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation. RSC Adv. 2019;9:19325\u201332. https:\/\/doi.org\/10.1039\/C9RA03251G.","journal-title":"RSC Adv"},{"key":"1015_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2125.2009.03370.x","volume":"67","author":"DA Smith","year":"2009","unstructured":"Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2009;67:421\u20136. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03370.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1015_CR13","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/0006-2952(85)90541-6","volume":"34","author":"KW Renton","year":"1985","unstructured":"Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol. 1985;34:2549\u201353. https:\/\/doi.org\/10.1016\/0006-2952(85)90541-6.","journal-title":"Biochem Pharmacol"},{"key":"1015_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0090-9556(24)15118-5","volume":"28","author":"B Ma","year":"2000","unstructured":"Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000;28:125\u201330. https:\/\/doi.org\/10.1016\/S0090-9556(24)15118-5.","journal-title":"Drug Metab Dispos"},{"key":"1015_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s13318-019-00602-7","volume":"45","author":"K Suzuki","year":"2020","unstructured":"Suzuki K, Taniyama K, Aoyama T, Watanabe Y. Evaluation of the role of P-glycoprotein (P-gp)-mediated efflux in the intestinal absorption of common substrates with elacridar, a P-gp inhibitor, in rats. Eur J Drug Metab Pharmacokinet. 2020;45:385\u201392. https:\/\/doi.org\/10.1007\/s13318-019-00602-7.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1015_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejim.2019.05.002","volume":"65","author":"P Gallo","year":"2019","unstructured":"Gallo P, De Vincentis A, Pedone C, Nobili A, Tettamanti M, Gentilucci UV, et al. Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med. 2019;65:51\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2019.05.002.","journal-title":"Eur J Intern Med"},{"key":"1015_CR17","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565\u201381. https:\/\/doi.org\/10.1016\/j.clpt.2006.09.003.","journal-title":"Clin Pharmacol Ther"},{"key":"1015_CR18","doi-asserted-by":"publisher","unstructured":"Methaneethorn J, Chamnansua M, Kaewdang N, Lohitnavy M. A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans. In: 2014 36th Annu Int Conf IEEE Eng Med Biol Soc EMBC 2014. 2014;5711\u20134. https:\/\/doi.org\/10.1109\/EMBC.2014.6944924.","DOI":"10.1109\/EMBC.2014.6944924"},{"key":"1015_CR19","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1470-2045(11)70040-7","volume":"12","author":"J Lees","year":"2011","unstructured":"Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12:1249\u201357. https:\/\/doi.org\/10.1016\/S1470-2045(11)70040-7.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1015_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/17576180.2024.2372162","volume":"16","author":"MP Desai","year":"2024","unstructured":"Desai MP, Patil PH, Shenoy GG, Channabasavaiah JP. Estimation of CDK inhibitors by RP-HPLC: application for pharmacokinetic interactions studies with PPIs. Bioanalysis. 2024;16(15):801\u201312. https:\/\/doi.org\/10.1080\/17576180.2024.2372162.","journal-title":"Bioanalysis"},{"key":"1015_CR21","unstructured":"FDA. Bioanalytical method validation guidance for industry. Bioanal Method Valid. 2018;1\u201344. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/ or http:\/\/www.fda.gov\/AnimalVeterinary\/GuidanceComplianceEnforcement\/GuidanceforIndustry\/default.htm."},{"issue":"2","key":"1015_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jpp\/rgad115","volume":"76","author":"PH Patil","year":"2023","unstructured":"Patil PH, Desai MP, Birangal S. Differential effects of dietary polyphenols on oral pharmacokinetics of cyclin-dependent kinase inhibitors in rats: a mechanistic framework for in vitro\u2013in vivo extrapolation. J Pharm Pharmacol. 2023;76(2):93\u2013105. https:\/\/doi.org\/10.1093\/jpp\/rgad115.","journal-title":"J Pharm Pharmacol"},{"key":"1015_CR23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s13318-024-00909-0","volume":"49","author":"PH Patil","year":"2024","unstructured":"Patil PH, Desai M, Birangal S, Gurupur GS, Rao M, Yadav A, et al. The effect of concomitant administration of proton pump inhibitors on the pharmacokinetics of CDK4\/6 inhibitors in rats: implications for the evaluation of hepatic and transporter-mediated drug-drug interactions. Eur J Drug Metab Pharmacokinet. 2024;49:631\u201344. https:\/\/doi.org\/10.1007\/s13318-024-00909-0.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1015_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2174\/1389200223666220218090948","volume":"23","author":"PH Patil","year":"2022","unstructured":"Patil PH, Jagadish PC, Fatima F, Birangal S, Shenoy GG, Rao M, et al. Inhibition of cytochrome P450 enzyme and drug-drug interaction potential of acid reducing agents used in management of CDK inhibitors for breast cancer chemotherapy. Curr Drug Metab. 2022;23:137\u201349. https:\/\/doi.org\/10.2174\/1389200223666220218090948.","journal-title":"Curr Drug Metab"},{"key":"1015_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105431","volume":"152","author":"C Fink","year":"2020","unstructured":"Fink C, Lecomte M, Badolo L, Wagner K, M\u00e4der K, Peters SA. Identification of solubility-limited absorption of oral anticancer drugs using PBPK modeling based on rat PK and its relevance to human. Eur J Pharm Sci. 2020;152:105431. https:\/\/doi.org\/10.1016\/j.ejps.2020.105431.","journal-title":"Eur J Pharm Sci"},{"key":"1015_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.critrevonc.2013.08.007","volume":"89","author":"A Thomas-Schoemann","year":"2014","unstructured":"Thomas-Schoemann A, Blanchet B, Bardin C, No\u00e9 G, Boudou-Rouquette P, Vidal M, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014;89:179\u201396. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.007.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1015_CR27","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/bcp.12563","volume":"79","author":"NJ Waters","year":"2015","unstructured":"Waters NJ. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment. Br J Clin Pharmacol. 2015;79:946\u201358. https:\/\/doi.org\/10.1111\/bcp.12563.","journal-title":"Br J Clin Pharmacol"},{"key":"1015_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1600-0773.1999.tb00085.x","volume":"85","author":"JS Wang","year":"1999","unstructured":"Wang JS, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, Kivist\u00f6 KT. Midazolam \u03b1-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol. 1999;85:157\u201361. https:\/\/doi.org\/10.1111\/j.1600-0773.1999.tb00085.x.","journal-title":"Pharmacol Toxicol"},{"issue":"2","key":"1015_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1378\/chest.96.2.393","volume":"96","author":"BA Hunt","year":"1989","unstructured":"Hunt BA, Self TH, Lalonde RL, Bottorff MB. Calcium channel blockers as inhibitors of drug metabolism. Chest. 1989;96(2):393\u20139. https:\/\/doi.org\/10.1378\/chest.96.2.393.","journal-title":"Chest"},{"key":"1015_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1124\/dmd.32.2.259","volume":"32","author":"YH Wang","year":"2004","unstructured":"Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004;32:259\u201366. https:\/\/doi.org\/10.1124\/dmd.32.2.259.","journal-title":"Drug Metab Dispos"},{"key":"1015_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/21556660.2013.785413","volume":"2","author":"R Teng","year":"2013","unstructured":"Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013;2:30\u20139. https:\/\/doi.org\/10.3109\/21556660.2013.785413.","journal-title":"J Drug Assess."},{"key":"1015_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/TCRM.S55512","volume":"10","author":"YT Zhou","year":"2014","unstructured":"Zhou YT, Yu LS, Zeng S, Huang YW, Xu HM, Zhou Q. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management. Ther Clin Risk Manag. 2014;10:17\u201326. https:\/\/doi.org\/10.2147\/TCRM.S55512.","journal-title":"Ther Clin Risk Manag"},{"key":"1015_CR33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1039\/C4MD00048J","volume":"5","author":"WC Wang","year":"2014","unstructured":"Wang WC, Shiao HY, Lee CC, Fung KS, Hsieh HP. Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery. Med Chem Commun. 2014;5:1266\u201379.","journal-title":"Med Chem Commun"},{"key":"1015_CR34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4062\/biomolther.2011.19.3.364","volume":"19","author":"C Li","year":"2011","unstructured":"Li C, Choi BC, Kim DK, Choi JS. Effects of curcumin on the pharmacokinetics of loratadine in rats: possible role of CYP3A4 and P-glycoprotein Inhibition by curcumin. Biomol Ther. 2011;19:364\u201370.","journal-title":"Biomol Ther"},{"key":"1015_CR35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3109\/00498254.2010.512670","volume":"40","author":"Y Li","year":"2010","unstructured":"Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW. In vitro assessment of metabolic drug-drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P450 enzyme identification, inhibition, and induction studies. Xenobiotica. 2010;40:721\u20139. https:\/\/doi.org\/10.3109\/00498254.2010.512670.","journal-title":"Xenobiotica"},{"key":"1015_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s13273-018-0027-z","volume":"14","author":"WS Lee","year":"2018","unstructured":"Lee WS, Kim J. Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy. Mol Cell Toxicol. 2018;14:247\u201354. https:\/\/doi.org\/10.1007\/s13273-018-0027-z.","journal-title":"Mol Cell Toxicol"},{"key":"1015_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.clpt.2005.11.001","volume":"79","author":"GL Lemma","year":"2006","unstructured":"Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006;79:218\u201330. https:\/\/doi.org\/10.1016\/j.clpt.2005.11.001.","journal-title":"Clin Pharmacol Ther"},{"key":"1015_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF00542456","volume":"22","author":"KE Pedersen","year":"1982","unstructured":"Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Pedersen KK. The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol. 1982;22:123\u20137. https:\/\/doi.org\/10.1007\/BF00542456.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01015-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01015-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01015-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:56:15Z","timestamp":1788980175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01015-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01015-z","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest associated with this publication.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institute's Animal Ethics Committee of Kasturba Medical College, Manipal, Review Board prior to the study (reference no. IAEC\/KMC\/93\/2021, approved on 23 October 2021). All experiments performed on rodents in this study were carred out in accordance with the ARRIVE guidelines.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Participation","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}